This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2009-0099v1 14/7/739    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lee, A. I. Articles by LaCasce, A. S. Search for Related Content PubMed PubMed Citation Articles by Lee, A. I. Articles by LaCasce, A. S.

Lymphoma

Nodular Lymphocyte Predominant Hodgkin Lymphoma

^aDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; ^bCenter for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Key Words. Hodgkin lymphoma • Nodular lymphocyte Hodgkin lymphoma • LP cell

Correspondence: Ann S. LaCasce, M.D., Center for Hematologic Oncology, Dana-Farber Cancer Institute, D1B05, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-5959; Fax: 617-632-3477; e-mail: Ann_Lacasce{at}dfci.harvard.edu

Received May 22, 2009; accepted for publication June 17, 2009; first published online in THE ONCOLOGIST Express on July 15, 2009.

Disclosures: Alfred Ian Lee: None; Ann S. LaCasce: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subtype of HL with unique clinicopathologic features. The hallmark histologic feature is the presence of malignant LP cells, unusual CD20⁺CD15^–CD30^– variants of Reed-Sternberg cells, embedded within a nodular pattern of infiltrating lymphocytes. Compared with classical HL, NLPHL shows a slightly older median age at presentation (30–40 years), greater male predominance (3:1), less mediastinal involvement (<15%), and lower occurrence of classical HL risk factors. The differential diagnosis includes progressive transformation of germinal centers, lymphocyte-rich classical HL, and T-cell/histiocyte-rich large B-cell lymphoma, the latter of which may share a common biologic relationship. The vast majority of patients present with limited stage disease (70%–80%), the standard treatment for which is involved field radiotherapy at 30–36 Gy. Response rates to primary therapy exceed 90%, although relapses are common and may occur years after the initial diagnosis. Secondary malignancies, particularly non-Hodgkin lymphoma, may also occur at a frequency similar to that of relapsed NLPHL. Patients with advanced stage disease may have lower response rates and overall survival times than those with limited stage disease. For relapsed disease, treatment options include the salvage therapies used in classical HL, and rituximab.